Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Lu AG06474 in Healthy Men
NCT05003687Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu ag06474 in neurological disorder and pain (2 arms), sponsored by Lundbeck. Primary endpoints: Treatment-Emergent Adverse Events, Delta QTcF Interval at Day 1 and 6 more. Started Aug 2021; status: completed.
02
Drugs
lu ag06474
03
Conditions
neurological disorderpain
Beyond the preview
Go deeper on NCT05003687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003687.